Contact
Contact
Contact

FDA Allows Marketing of Cooling Cap to Reduce Hair Loss During Chemotherapy

The first Dignicap was introduced in Romania in 2012 by our clinic in order to prevent hair loss during chemotherapy and to improve our patients’ quality of life.

The U.S. Food and Drug Administration has cleared the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy for marketing in the United States.

Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of breast cancer. Hair may fall out entirely, gradually, in sections, or may become thin. Hair loss due to cancer treatment is usually temporary, but minimizing or relieving these kinds of side effects are considered important to overall treatment.

“We are pleased to see a product for breast cancer patients that can minimize chemotherapy-induced hair loss and contribute to the quality of life of these individuals,” said William Maisel, MD, MPH, Acting Director of the Office of Device Evaluation in the FDA’s Center for Devices and Radiological Health. “Managing the side effects of chemotherapy is a critical component to overall health and recovery.”

Read more here: The ASCO Post